The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line ...
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback